Skip to main content
Home Licenses Page 3

Have Questions?

Please contact us or subscribe for more opportunities

Stay in Touch with Us

https://otc.duke.edu/wp-content/uploads/2022/08/Xilis-logo-for-social-1.png

Xilis Participates in €325MM Oncode-PACT Consortium to Accelerate the Development of Cancer Drugs

National public-private consortium aims to bring together researchers, oncologists, knowledge institutes and the business community to collaboratively develop better and affordable cancer medicines more quickly DURHAM, N.C., May 3, 2022–(BUSINESS WIRE)–Xilis, Inc., a pioneering company…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/presentation-PGF388T-1.jpg

Pitfalls When Speaking with Industry

Great news – a company has asked to set up an introductory meeting to hear more about your invention! These meetings are great opportunities to take steps towards bringing your technology to market through a…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/Translation-Research-Week-2022-2.png

Different Roads to Translation

From left to right: Robin Rasor, Matthew Becker, PhD, Arif kamal, MD, MBA, Howard Levinson, MD, Stefan Roberts, PhD.   By Aliza Inbari The Duke Office for Translation and Commercialization receives about 400 invention disclosures…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/rasor_HERO-1.jpeg

The Role of a University Technology Transfer Office in Moving Great Ideas Forward

“You may have great technology, but if you don’t have the right talent or the right team, it’s hard to get the investment, certainly from venture firms. We spend a lot of time trying to…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/Precision-Molecular-1.png

Precision Molecular Inc. Executes License for Exclusive Rights to an Astatine-211-Labeled Radiopharmaceutical Inhibitor of Prostate-Specific Membrane Antigen for Prostate Cancer Therapeutics

  Currently in IND-enabling studies, PMI21 is expected to advance into clinical trials in patients with metastatic prostate cancer in 2022 Astatine-211 labelling offers important advantages in terms of potency and safety of radiopharmaceuticals as…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/innovation-and-creative-idea-concept-W8NTDXC-1.jpg

Bringing Inventions to the Market

  By Aliza Inbari Universities are great innovation incubators. Google, flu shots, vaccines, GPS, and many other inventions were born in university labs around the world and impact our lives every day. The Duke Office…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/Dr-Louis-Markert-1.jpg

After Decades of Research, Drug Developed at Duke Receives FDA Approval

Dr. Louise Markert (left) with patient Jayla Turner in 2016.   By Sarah Avery DURHAM, N.C., October 11, 2021 – The phone rang into the pediatric unit that Louise Markert, M.D., Ph.D., was staffing as…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/logo-splendo-blue-2.png

Duke Signed a License Agreement with Splendo Health

Duke University and Splendo Health have entered into a license agreement. The Dutch digital health startup is a collaboration between Duke University and Splendo Consulting. Splendo Health has developed SplendoFit, a comprehensive digital platform with sensors and…

Read More

https://otc.duke.edu/wp-content/uploads/2022/08/surgery-stock-photo-1.jpeg

Predictive Technology Developed at Duke Promises to Reduce Inefficiencies in Surgery

“We were able to take a Duke-born technology, foster and pilot it in the entrepreneurial environment of Duke to the point it could be translated out as a start-up, partner with Duke to bring a…

Read More